Huntington’s Disease - Pipeline Assessment and Market Forecasts to 2017 The Huntington’s Therapeutics Disease Market is Forecast to Show High Growth Until 2017 The global Huntington’s Disease (HD) market was worth $142m in 2009. The market is expected to grow by 39.6% during the next seven years to reach $2 billion by 2017. Earlier, the HD therapeutics market was underserved as no approved medication was available. The off label usage of antipsychotics, mood stabilizers, anti-depressants and antiepileptics existed for the symptomatic treatment of HD. Biovail’s Xenazine (tetrabenazine), approved in November 2008, is the first approved treatment option for the chorea (uncontrolled movements) associated with HD. The pipeline has a number of first-in-class molecules which are expected to be launched in the near future. If approved, the upcoming therapies will compete with Xenazine, leading to a market share war. Xenazine will be the primary driver for the HD market until the launch of any late stage pipeline molecules. Essentially, the global HD market is heading towards a phase of continuous growth, leveraging the current opportunities. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Huntingtons-Disease-DrugPipeline-Analysis-and-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare GlobalData analyzed and found the current competition in the HD market to be weak. The market is underserved with only one approved product, Xenazine, which was the first approved drug to enter the HD market for the treatment of the chorea associated with HD. Although Xenazine failed to serve the market as a curative therapy, it has shown a positive uptake. While the market remains underserved by current therapies, the newer candidates will have substantial scope for growth and profitability.Antipsychotics and antiepileptics are the most widely prescribed treatment options for HD. Xenazine has been successful in leveraging the untapped potential of the market. The competition is anticipated to be fierce, with the launch of late stage pipeline molecules expected to lead to a market share war. GlobalData, the industry analysis specialist, has released its new report, “Huntington’s Disease -Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Huntington’s disease therapeutics market and pipeline. The report identifies the key trends shaping and driving the global Huntington’s Disease therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global muscular dystrophy therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Huntingtons-Disease-DrugPipeline-Analysis-and-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782